Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK
Fig 2
Risk of CV hospitalization at 14 days stratified by concomitant P-glycoprotein medication prescription.
Hazard ratio adjusted using the likelihood of clarithromycin prescription as a covariate (inverse probability of treatment weighting)—this included the following variables: age at prescription, sex, prior history of chronic obstructive pulmonary disease, prior myocardial infarction, history of type 2 diabetes, left ventricular systolic function impairment, and all medications listed in Table 1. CCB, calcium channel blocker; CI, confidence interval; CV, cardiovascular.